RSS   Newsletter   Contact   Advertise with us

Female Viagra creator Sprout Pharma to be sold to Valeant for $1 billion

Staff writer ▼ | August 20, 2015
Valeant Pharmaceuticals International will buy Sprout Pharmaceuticals, whose drug this week became the first approved treatment for low sexual desire in women, for about $1 billion plus milestone payments.
Sprout Pharmaceuticals
Acquisition   Addyi was approved by the U.S. Food and Drug Administration
Sprout's pill Addyi was approved on Tuesday by the U.S. Food and Drug Administration (FDA) for pre-menopausal women, after being rejected twice over concerns about its effectiveness and side-effects.

Addyi, popularly known as the "female Viagra", carries a strong warning about potentially dangerous low blood pressure and fainting, especially when taken with alcohol, raising some doubts about its commercial prospects.

Unlike Pfizer's Viagra, which affects blood flow to the genitals, Addyi is meant to activate sexual impulses in the brain.

Sprout, based in Raleigh, N. C., was co-founded in 2011 by husband and wife Cindy and Robert Whitehead. They sold another small drugmaker they founded, Slate Pharmaceuticals.


 

MORE INSIDE POST